Page 103 - 《中国药房》2022年19期

diovascular events[J]. N Engl J Med，2015，372（16）： submitted to FAERS[J]. Clin Drug Investig，2019，39（3）：
1489-1499. 319-330.
[ 9 ] LIPINSKI M J，BENEDETTO U，ESCARCEGA R O， [18] SIAFIS S，PAPAZISIS G. Detecting a potential safety
et al. The impact of proprotein convertase subtilisin-kexin signal of antidepressants and type 2 diabetes：a
type 9 serine protease inhibitors on lipid levels and out‐ pharmacovigilance-pharmacodynamic study[J]. Br J Clin
comes in patients with primary hypercholesterolaemia：a Pharmacol，2018，84（10）：2405-2414.
network meta-analysis[J]. Eur Heart J，2016，37（6）： [19] BJÖRKHEM I，MEANEY S. Brain cholesterol：long
536-545. secret life behind a barrier[J]. Arterioscler Thromb Vasc
[10] KHAN A R，BAVISHI C，RIAZ H，et al. Increased risk of Biol，2004，24（5）：806-815.
adverse neurocognitive outcomes with proprotein conver‐ [20] JOSEPH J A，DENISOVA N，VILLALOBOS-MOLINA R，
tase subtilisin-kexin type 9 inhibitors[J]. Circ Cardiovasc et al. Oxidative stress and age-related neuronal deficits[J].
Qual Outcomes，2017，10（1）：e003153. Mol Chem Neuropathol，1996，28（1-3）：35-40.
[11] BAJAJ N S，PATEL N，KALRA R，et al. Neurological [21] O’CONNELL E M，LOHOFF F W. Proprotein convertase
effects of proprotein convertase subtilisin/kexin type 9 subtilisin/kexin type 9（PCSK9）in the brain and rele-
inhibitors：direct comparisons[J]. Eur Heart J Qual Care vance for neuropsychiatric disorders[J]. Front Neurosci，
Clin Outcomes，2018，4（2）：132-141. 2020，14：609.
[12] HARVEY P D，SABBAGH M N，HARRISON J E，et al. [22] MANNARINO M R，SAHEBKAR A，BIANCONI V，et al.
No evidence of neurocognitive adverse events associated PCSK9 and neurocognitive function：should it be still an
with alirocumab treatment in 3 340 patients from 14 rando- issue after FOURIER and EBBINGHAUS results? [J]. J
mized Phase 2 and 3 controlled trials：a meta-analysis of Clin Lipidol，2018，12（5）：1123-1132.
individual patient data[J]. Eur Heart J，2018，39（5）： [23] ADORNI M P，RUSCICA M，FERRI N，et al. Proprotein
374-381. convertase subtilisin/kexin type 9，brain cholesterol
[13] HIRSH RACCAH B，YANOVSKY A，TREVES N，et al. homeostasis and potential implication for Alzheimer’s
Proprotein Convertase Subtilisin/Kexin Type 9（PCSK9） disease[J]. Front Aging Neurosci，2019，11：120.
inhibitors and the risk for neurocognitive adverse events：a [24] REITZ C. Dyslipidemia and dementia：current epidemiology，
systematic review，meta-analysis and meta-regression[J]. genetic evidence，and mechanisms behind the associations
Int J Cardiol，2021，335：7-14. [J].J Alzheimers Dis，2012，30，Suppl 2（2）：S127-S145.
[14] KIM H S，LEE S，KIM J H. Real-world evidence versus [25] GÜRGÖZE M T，MULLER-HANSMA A H G，SCHREUDER
randomized controlled trial：clinical research based on M M，et al. Adverse events associated with PCSK9 inhibi‐
electronic medical records[J]. J Korean Med Sci，2018，33 tors：a real-world experience[J]. Clin Pharmacol Ther，
（34）：e213. 2019，105（2）：496-504.
[15] ROBIN X，TURCK N，HAINARD A，et al. pROC：an [26] MEFFORD M T，ROSENSON R S，CUSHMAN M，et al.
open-source package for R and S+ to analyze and PCSK9 variants，low-density lipoprotein cholesterol，and
compare ROC curves[J]. BMC Bioinformatics，2011， neurocognitive impairment：reasons for geographic and
12：77. racial differences in stroke study（REGARDS）[J]. Circu‐
[16] BÖHM R，VONHEHN L，HERDEGEN T，et al. Open‐ lation，2018，137（12）：1260-1269.
Vigil FDA-inspection of US American adverse drug [27] GIUGLIANO R P，MACH F，ZAVITZ K，et al. Cogni‐
events pharmacovigilance data and novel clinical applica‐ tive function in a randomized trial of evolocumab[J]. N
tions[J]. PLoS One，2016，11（6）：e0157753. Engl J Med，2017，377（7）：633-643.
[17] JI H H，TANG X W，DONG Z，et al. Adverse event pro‐ （收稿日期：2022-03-10 修回日期：2022-07-26）
files of anti-CTLA-4 and anti-PD-1 monoclonal antibodies （编辑：舒安琴）
alone or in combination：analysis of spontaneous reports

中国药房 2022年第33卷第19期 China Pharmacy 2022 Vol. 33 No. 19 ·2397·